atezolizumab + durvalumab + trastuzumab

This is a **triple antibody combination therapy** consisting of **atezolizumab** (an anti–PD-L1 monoclonal antibody), **durvalumab** (another anti–PD-L1 antibody), and **trastuzumab** (an anti–HER2 monoclonal antibody). Each targets a different immunological or growth pathway: - *Atezolizumab and durvalumab* both block programmed cell death ligand 1 (**PD-L1**), removing immunosuppression in the tumor microenvironment and enhancing T-cell antitumor activity[2][5][14]. - *Trastuzumab* targets the human epidermal growth factor receptor 2 (**HER2/Epitope IV**), interfering with HER2 signaling and marking HER2+ tumor cells for immune-mediated destruction, particularly antibody-dependent cell-mediated cytotoxicity[1]. There are no published clinical trials of this exact triple combination in a single regimen; instead, dual combinations (e.g., atezolizumab and trastuzumab+chemotherapy or durvalumab and trastuzumab) have been explored in HER2-positive cancers, especially breast and gastric cancer. The rationale for such combinations is the potential synergy between immune checkpoint blockade and HER2 inhibition, possibly overcoming resistance to HER2-targeted therapy[5][7][6].

Other names

atezolizumab + durvalumab + trastuzumab